WO2005099721A3 - Compositions comportant des composes polyphenoliques derives de plantes et des inhibiteurs d'especes reactive d'oxygene et leurs procedes d'utilisation - Google Patents

Compositions comportant des composes polyphenoliques derives de plantes et des inhibiteurs d'especes reactive d'oxygene et leurs procedes d'utilisation Download PDF

Info

Publication number
WO2005099721A3
WO2005099721A3 PCT/US2005/011741 US2005011741W WO2005099721A3 WO 2005099721 A3 WO2005099721 A3 WO 2005099721A3 US 2005011741 W US2005011741 W US 2005011741W WO 2005099721 A3 WO2005099721 A3 WO 2005099721A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
oxygen species
reactive oxygen
compositions
inhibitors
Prior art date
Application number
PCT/US2005/011741
Other languages
English (en)
Other versions
WO2005099721A2 (fr
Inventor
Stephen Pandol
Anna Gukovskaya
Moussa Yazbeck
Guido Eibl
Laszlo Boros
Akihiko Sato
Original Assignee
Univ California
Stephen Pandol
Anna Gukovskaya
Moussa Yazbeck
Guido Eibl
Laszlo Boros
Akihiko Sato
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/824,597 external-priority patent/US20040259816A1/en
Application filed by Univ California, Stephen Pandol, Anna Gukovskaya, Moussa Yazbeck, Guido Eibl, Laszlo Boros, Akihiko Sato filed Critical Univ California
Publication of WO2005099721A2 publication Critical patent/WO2005099721A2/fr
Publication of WO2005099721A3 publication Critical patent/WO2005099721A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention a trait à des procédés pour le traitement, la prévention, ou l'inhibition de maladies et de troubles associés à l'activation de NF-Kb comprenant des maladies proliférantes telles que le cancer et des maladies inflammatoires telles que la pancréatite chez un sujet comprenant l'administration d'au moins un composé polyphénolique et/ou au moins un inhibiteur d'espèce réactive d'oxygène, L'invention a également trait à des compositions pharmaceutiques comportant au moins un composé phénolique et/ou au moins un inhibiteur d'espèce réactive d'oxygène. Le composé polyphénolique peut être dérivé ou isolé à partir de plantes. Dans certains modes de réalisation, le composé polyphénolique est de type non flavonoïde. L'invention a trait en outre à d'autres procédés et trousses ainsi qu'à des compositions pharmaceutiques.
PCT/US2005/011741 2004-04-15 2005-04-07 Compositions comportant des composes polyphenoliques derives de plantes et des inhibiteurs d'especes reactive d'oxygene et leurs procedes d'utilisation WO2005099721A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56231504P 2004-04-15 2004-04-15
US10/824,597 2004-04-15
US10/824,597 US20040259816A1 (en) 2002-10-01 2004-04-15 Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
US60/562,315 2004-04-15

Publications (2)

Publication Number Publication Date
WO2005099721A2 WO2005099721A2 (fr) 2005-10-27
WO2005099721A3 true WO2005099721A3 (fr) 2008-10-09

Family

ID=35150498

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/011741 WO2005099721A2 (fr) 2004-04-15 2005-04-07 Compositions comportant des composes polyphenoliques derives de plantes et des inhibiteurs d'especes reactive d'oxygene et leurs procedes d'utilisation

Country Status (1)

Country Link
WO (1) WO2005099721A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008026125A2 (fr) * 2006-09-01 2008-03-06 Piramal Life Sciences Limited Utilisation d'acide caféique et de dérivés de ce composé comme anticancéreux
US20090048174A1 (en) * 2006-12-08 2009-02-19 Mochly-Rosen Daria D Methods for inhibiting angiogenesis and tumor growth by inhibition of beta or delta protein kinase C
US8734867B2 (en) 2007-12-28 2014-05-27 Liveleaf, Inc. Antibacterial having an extract of pomegranate combined with hydrogen peroxide
EP2119434A1 (fr) * 2008-05-13 2009-11-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation de dérivés flavonoïdes hétérosidiques pour la thérapie de cancers de cellules souches
FR2954352B1 (fr) 2009-12-21 2012-09-28 Roussy Inst Gustave Marqueur de predisposition a un cancer
ES2385157B1 (es) * 2010-02-25 2013-07-08 Universidad Del País Vasco Compuestos para el tratamiento de alzheimer.
CN102462674B (zh) * 2010-11-04 2014-04-02 刘丽宏 姜黄素及其衍生物在制备治疗人巨细胞病毒感染药物中的应用
US8722040B2 (en) 2011-06-24 2014-05-13 Liveleaf, Inc. Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites
US9192635B2 (en) 2011-06-24 2015-11-24 Liveleaf, Inc. Method of treating damaged mucosal or gastrointestinal tissue by administering a composition comprising a mixture of pomegranate and green tea extracts and releasably bound hydrogen peroxide
EP2578210A1 (fr) * 2011-10-05 2013-04-10 ATB Innovation Ltd. Rottlerine pour le traitement de l'hypertension pulmonaire et de maladies et troubles apparentés
ES2428665B1 (es) * 2012-05-04 2014-10-01 Universidad De Valladolid Composición para su uso en el tratamiento y/o prevención de la inflamación, el estrés oxidativo y la neovascularización ocular
US8716351B1 (en) 2012-12-23 2014-05-06 Liveleaf, Inc. Methods of treating gastrointestinal spasms
US11497749B2 (en) * 2017-10-24 2022-11-15 Lunella Biotech, Inc. Mitoflavoscins: targeting flavin-containing enzymes eliminates cancer stem cells (CSCS) by inhibiting mitochondrial respiration
CN113425710A (zh) * 2021-07-08 2021-09-24 四川九章生物科技有限公司 绿原酸在制备治疗中枢神经系统肿瘤的药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821072A (en) * 1996-02-20 1998-10-13 Sloan-Kettering Institute For Cancer Research Combinations of PKC inhibitors and therapaeutic agents for treating cancers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821072A (en) * 1996-02-20 1998-10-13 Sloan-Kettering Institute For Cancer Research Combinations of PKC inhibitors and therapaeutic agents for treating cancers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GSCHWENDT ET AL.: "Rottlerin, a novel protein kinase inhibitor", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 199, no. 1, 28 February 1994 (1994-02-28), pages 93 - 98 *
MOURIA ET AL.: "Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis", INT. J. CANCER, vol. 98, 2002, pages 761 - 769, XP003013983, DOI: doi:10.1002/ijc.10202 *

Also Published As

Publication number Publication date
WO2005099721A2 (fr) 2005-10-27

Similar Documents

Publication Publication Date Title
WO2005099721A3 (fr) Compositions comportant des composes polyphenoliques derives de plantes et des inhibiteurs d'especes reactive d'oxygene et leurs procedes d'utilisation
WO2007139960A3 (fr) Composés modulant l'activité de hsp90 et méthodes d'identification de ces composés
WO2006091395A3 (fr) Inhibiteurs d'activite d'akt
WO2008070016A3 (fr) Inhibiteurs de l'activité akt
WO2010074588A8 (fr) Composés pharmaceutiques
WO2008011363A3 (fr) Compositions contenant de la quercétine
WO2007095124A3 (fr) Derives, compositions de benzazole et procedes d'utilisation en tant qu'inhibiteurs de la kinase aurora
WO2007139955A3 (fr) Composés de triazole qui modulent l'activité de la hsp90
WO2007139967A3 (fr) Composés de triazole modulant l'activité de hsp90
WO2007139968A3 (fr) Composés de triazole qui modulent l'activité de la hsp90
WO2006135627A3 (fr) Inhibiteurs de l'activite akt
WO2006110638A3 (fr) Inhibiteur de l'activite akt
WO2008005511A8 (fr) Nouveaux inhibiteurs de la réplication du virus de l'hépatite c
EP1748767A4 (fr) Diarylalcanes constituant des inhibiteurs puissants d'enzymes binucleaires
WO2010001169A3 (fr) Composés chimiques 251
WO2007094819A8 (fr) Dérivés de triazole modulant l'activité de hsp90
WO2010033977A3 (fr) Composes multiheteroaryles servant d'inhibiteurs de la h-pgds, ainsi que leur utilisation dans le traitement des maladies induites par la prostaglandine d2
WO2007109279A3 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
WO2007077260A8 (fr) Formules de faible teneur en huile comprenant des dérivés de diphénylméthane
WO2008042282A3 (fr) Modulateurs de jak-2 et méthodes d'utilisation
WO2008036379A3 (fr) Inhibiteurs de serine hydrolase
WO2008030795A3 (fr) Compositions et procédés d'inhibition de tyrosine kinases
WO2005105770A3 (fr) Derives de sulfure d'arylphenylamine, d'arylphenylamide, et d'arylphenylether
MY148647A (en) Pharmaceutical compositions comprising a camtothecin derivative
WO2006068796A3 (fr) Inhibiteurs de l'activite de akt

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase